| Literature DB >> 35221520 |
Anna Eliason1,2, Suzanne Werner1, Björn Engström1,3, Marita Harringe1.
Abstract
[Purpose] To investigate if joint mobilization in patients with subacromial pain syndrome has additional benefits to a home training program on shoulder function and pain, and to compare home training to no physical therapy. [Participants and Methods] Eighty-nine primary care patients (mean age 45 years) with subacromial pain syndrome during an average of 23 weeks. Home training was performed twice a day during a 12 week period. One of the intervention groups received add-on shoulder joint mobilization to the home training. A third group did not receive any physical therapy. Constant-Murley score, pain and active range of motion was evaluated at baseline, 6 weeks, 12 weeks and 6 months.Entities:
Keywords: Constant-Murley score; Joint mobilization; Shoulder pain
Year: 2022 PMID: 35221520 PMCID: PMC8860700 DOI: 10.1589/jpts.34.153
Source DB: PubMed Journal: J Phys Ther Sci ISSN: 0915-5287
Patient characteristics at baseline
| Variable | MG (n=20) | HG (n=30) | RG (n=39) | |
| Male/Female | n | 7/12 | 14/16 | 19/20 |
| Age (years) | m (SD) | 43 ± 11 | 43 ± 12 | 46 ± 10 |
| Physical activity (times/week) | m (SD) | 1.6 ± 1.5 | 1.1 ± 1.3 | 1.7 ± 1.7 |
| Dominant arm, right | n (%) | 18 (90) | 27 (90) | 38 (97) |
| Symptomatic arm=dominant | n (%) | 12 (60) | 20 (67) | 26 (67) |
| Duration of pain (weeks) | m (SD) | 24 ± 13 | 22 ± 14 | 24 ± 17 |
| Slow debut | n (%) | 18 (90) | 27 (90) | 35 (90) |
| Pain at rest | n (%) | 11 (55) | 19 (66)* | 24 (62) |
| Pain at movement | n (%) | 20 (100) | 29 (100)* | 39 (100) |
| Pain at compression | n (%) | 16 (80) | 26 (90)* | 33 (85) |
| Analgesics (NSAID’s) | n (%) | 11 (55) | 22 (76)* | 26 (67) |
MG: joint mobilization and home training group; HG: home training group; RG: reference group. *n=29 (one missing answer).
Fig. 1.Flow-chart of the patients throughout the entire study reported following the recommendations of the Consolidated Standards of Reporting Trials (CONSORT).
Inj: Injection, *ref18).
Shoulder function measured with Constant-Murley score in patients with subacromial pain syndrome
| Total C-M Score: | ||||
| group | Baseline | 6 weeks | 12 weeks | 6 months |
| MG | 36.4 (30.1–42.8) | 45.6 (38.3–52.8) | 57.3 (49.7–64.9) | 65.2 (59.3–71.1) |
| HG | 39.1 (36.2–42.0) | 45.3 (41.4–49.2) | 55.0 (50.0–60.0) | 58.8 (53.4–64.2) |
| RG | 40.1 (36.9–43.2) | 46.2 (42.9–49.6) | 51.3 (48.2–54.4) | 57.6 (53.7–61.6) |
| Change score: | 0–6 weeks | 0–12 weeks | 0–6 months | |
| MG | 9.2 (8.2–10.0) | 20.9*(19.6–22.1) | 28.8 (29.2–28.3) | |
| HG | 6.2 (5.2–7.2) | 15.9 (13.8–18.0) | 19.7 (17.2–22.2) | |
| RG | 6.2 (7.2–11.4) | 11.2 (7.2–11.3) | 17.6 (9.7–15.3) | |
The total score and the improvement from baseline to the three evaluation times, called the change-score, is presented with mean values and 95% confidence intervals (CI).
C-M: Constant-Murley; MG: Joint-mobilization + Home exercise group; HG: Home training group; RG: Reference group.
*: Clinical important change ≥17–18 points28, 32).
Proportions of yes-answers and 95% CI for pain at rest, pain in movement, pain at compression and medicine at the different evaluation times
| Pain at rest | Baseline | 6 weeks | 12 weeks | 6 months |
| MG | 0.58 (0.36–0.80) | 0.32 (0.11–0.53) | 0.24 (0.04–0.44) | 0.08 (0.65–0.94) |
| HG | 0.66 (0.49–0.83) | 0.34 (0.17–0.51) | 0.28 (0.10–0.46) | 0.23 (0.07–0.39) |
| RG | 0.62 (0.47–0.77) | 0.39 (0.22–0.56) | 0.47 (0.29–0.65) | 0.36 (0.20–0.52) |
| Pain in movement | Baseline | 6 weeks | 12 weeks | 6 months |
| MG | 1.00 | 1.00 | 0.76 (0.04–0.44) | 0.54 (0.27–0.81) |
| HG | 1.00 | 0.97 (0.90–1.04) | 0.84 (0.70–0.98) | 0.69 (0.51–0.87) |
| RG | 1.00 | 0.97 (0.91–1.03) | 0.93 (0.84–1.02) | 0.85 (0.73–0.97) |
| Pain at compression | Baseline | 6 weeks | 12 weeks | 6 months |
| MG | 0.84 (0.68–1.00) | 0.68 (0.47–0.89) | 0.41 (0.18–0.64) | 0.24 (0.06–0.42) |
| HG | 0.90 (0.80–1.00) | 0.76 (0.61–0.91) | 0.56 (0.36–0.76) | 0.46 (0.27–0.65) |
| RG | 0.82 (0.70–0.94) | 0.64 (0.56–0.72) | 0.57 (0.39–0.75) | 0.48 (0.31–0.65) |
| NSAID | Baseline | 6 weeks | 12 weeks | 6 months |
| MG | 0.55 (0.33–0.77) | 0.21 (0.19–0.23) | 0.12 (–0.03–0.27) | 0.00 |
| HG | 0.73 (0.57–0.89) | 0.34 (0.17–0.34) | 0.24 (0.07–0.41) | 0.04 (–0.03–0.11) |
| RG | 0.90 (0.84–0.95) | 0.24 (0.09–0.39) | 0.10 (–0.01–0.21) | 0.19 (0.05–0.32) |
MG: joint mobilization and home training group; HG: home training group; RG: reference group; NSAID: Non-Steroidal Anti-inflammatory Drugs.
Pain measured with a Visual Analog Scale (VAS) in active range of motion from baseline to the evaluation time at 6 weeks, 12 weeks and 6 months
| Active ROM | MG VAS pain | HG VAS pain | RG VAS pain | MG vs. HG | MG vs. RG | HG vs. RG | |
| MD (range) | MD (range) | MD (range) | |||||
| Flexion | Baseline | 30 (0–70) | 26.5 (0–70) | 31 (0–72) | |||
| 6 weeks | 24 (0–60) | 32 (0–76) | 26 (0–70) | ||||
| 12 weeks | 0* (0–36) | 0* (0–50) | 20 (0–69) | 0.000 | 0.002 | 0.000 | |
| 6 months | 0* (0–30) | 10* (0–82) | 0* (0–90) | 0.000 | |||
| Abduction | Baseline | 36 (0–70) | 38 (0–95) | 45 (9–76) | |||
| 6 weeks | 22.5 (0–62) | 30 (0–95) | 27* (0–85) | ||||
| 12 weeks | 10* (0–65) | 18* (0–66) | 15* (0–70) | ||||
| 6 months | 0* (0–70) | 15* (0–65) | 5* (0–92) | 0.037 | 0.002 | 0.050 | |
| External rotation | Baseline | 18 (0–64) | 28.5 (0–81) | 22 (0–71) | |||
| 6 weeks | 21 (0–70) | 26 (0–70) | 24 (0–89) | ||||
| 12 weeks | 0* (0–45) | 4* (0–76) | 10 (0–77) | 0.005 | 0.047 | ||
| 6 months | 0* (0–37) | 8* (0–71) | 4* (0–87) | 0.025 | 0.008 | ||
| Internal rotation | Baseline | 39 (0–88) | 42.5 (6–75) | 33 (0–87) | |||
| 6 weeks | 28 (0–76) | 28* (0–82) | 30 (0–90) | ||||
| 12 weeks | 17* (0–50) | 0* (0–5) | 22* (0–65) | 0.000 | 0.000 | ||
| 6 months | 0* (0–26) | 13* (0–79) | 9* (0–88) | 0.012 | 0.008 | ||
Data is analyzed with ANOVA and, when significant, pairwise compared with the Mann-Whitney U test.
p-values for the between group differences are presented when significant.
MG: joint mobilization and home training group; HG: home training group; RG: reference group; VAS: Visual Analog Scale=0–100 mm. *VAS ≥14 mm=Minimal clinical important improvement (MCID)31).